Gain Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Gain Therapeutics

26/03/2024 12:42

* Gain Therapeutics Inc  GANX.OQ  reported a quarterly
adjusted
loss of 36 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -39 cents.  The mean expectation of
five analysts for the quarter was for a loss of 32 cents per
share. Wall Street expected results to range from -40 cents
to -26 cents per share.
    * Reported revenue was zero​; analysts expected $325.00
thousand. 
    * Gain Therapeutics Inc's reported EPS for the quarter was a
loss
of 36 cents​.
    * The company reported a quarterly loss of $4.73 million.
    * Gain Therapeutics Inc shares had risen by 11.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Gain Therapeutics
Inc is $9.00 
This summary was machine generated from LSEG data March 26 at
12:42 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.32          -0.36          Missed
 Sep. 30 2023      -0.45          -0.37          Beat
 Jun. 30 2023      -0.31          -0.62          Missed
 Mar. 31 2023      -0.39          -0.43          Missed